Moreover, endogenous galectin-1 plays a key role in tumour immune privilege due to its capacity to induce apoptosis in activated T cells [7], which is relatively similar to the immunomodulatory properties of HSCs. The gene discussed is LGALS1; the disease is neoplasm.